# JAKARTA2 (NCT01523171)

> Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01523171
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Bristol-Myers Squibb
- Conditions: Hematopoietic Neoplasm
- Interventions: SAR302503
- Enrollment: 97
- Primary outcome: Response Rate: Percentage of Participants With >=35% Reduction From Baseline in Spleen Volume at End of Cycle 6

## Commentary we found

- YouTube: 21
- Podcasts: 13
- X threads: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=jakarta2-nct01523171

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01523171", "email": "<work email>"}; the inbox owner confirms by the emailed link.